ML 2-14
ML 2-14 is a PROTAC targeting BRD4 with a C4 alkyl linker. ML 2-14 consists of the E3 ligase ligand EN219 (bule part), the target protein ligand JQ-1 (HY-13030) (red part), and the PROTAC linker (balck part). ML 2-14 can effectively degrade BRD4 in 231MFP breast cancer cells, and this effect can be reversed by the proteasome inhibitor Bortezomib (HY-10227) and the E1 activase inhibitor TAK-243 (HY-100487).
Product Specifications
UNSPSC
12352005
Target
Epigenetic Reader Domain; PROTACs
Type
Reference compound
Related Pathways
Epigenetics; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ml-2-14.html
Purity
99.43
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
ClC1=CC=C(C=C1)C2=N[C@@H](CC(NCCCCOC3=CC=C(C4CC(C5=CC=C(Br)C=C5)=NN4C(CCl)=O)C=C3)=O)C6=NN=C(C)N6C7=C2C(C)=C(C)S7
Molecular Formula
C40H38BrCl2N7O3S
Molecular Weight
847.65
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
